Immunocure Inc

Immunocure Inc company information, Employees & Contact Information

Explore related pages

Related company profiles:

Transforming Drug Discovery through AxDrug & Synthesis Expertise AxDrug, our state-of-the-art AI engine, revolutionizes the drug discovery landscape by swiftly identifying promising "hit" molecules with unparalleled accuracy. At Immunocure, we don't stop at identification. With our in-house chemistry lab, we design, synthesize, and deliver molecules to our clients, analyzing assay results and progressing to the Lead optimization stage. Global Reach, Local Excellence While headquartered in the USA, our scientific team and lab in India ensure cutting-edge solutions at competitive rates, facilitating a seamless R&D journey without financial strain. Our Core Values, Your Guaranteed Success At Immunocure, our partnership is built on a foundation of innovation, integrity, commitment, trust, transparency, accountability, loyalty, and respect. With unwavering dedication, we ensure your success becomes our own. Unleashing Knowledge Beyond the Molecular Level Deep insights into molecular interactions at the atomic level, powered by computational methods, unlock unprecedented potential. Through machine learning tools, we transform data into actionable knowledge, empowering us in drug discovery from hit identification to lead optimization and beyond. AxDrug: Pioneering Your R&D Voyage AxDrug, our proprietary AI platform, seamlessly orchestrates the entire R&D process—from hit identification to lead optimization and deployment—with unparalleled efficiency and automation. Forge Ahead with the AI-Powered Trailblazers Beyond mere service providers, we are your trusted research partner. Join us on a transformative discovery journey fueled by AI and human ingenuity. Together, let's unlock the future of medicine.
Looking for a particular Immunocure Inc employee's phone or email?

Immunocure Inc Questions

News

Immuno Cure and PharmaJet collaborate to advance a novel HIV therapeutic DNA vaccine using needle-free technology in humans - European AIDS Treatment Group

Immuno Cure and PharmaJet collaborate to advance a novel HIV therapeutic DNA vaccine using needle-free technology in humans European AIDS Treatment Group

Immuno Cure, Pharmjet partner on needle-free HIV vaccine trial - BioWorld MedTech

Immuno Cure, Pharmjet partner on needle-free HIV vaccine trial BioWorld MedTech

and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine - Business Wire

and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine Business Wire

Immuno Cure and PharmaJet advance novel HIV therapeutic DNA vaccine using needle-free technology in humans - BioSpectrum Asia

Immuno Cure and PharmaJet advance novel HIV therapeutic DNA vaccine using needle-free technology in humans BioSpectrum Asia

Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition #ImmunoCure #醫克生物 #医克生物 - Media OutReach Newswire

Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition #ImmunoCure #醫克生物 #医克生物 Media OutReach Newswire

Immuno Cure and PharmaJet Partner for Needeless Injection with HIV Vaccine - Pharmaceutical Executive

Immuno Cure and PharmaJet Partner for Needeless Injection with HIV Vaccine Pharmaceutical Executive

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine - Laotian Times

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine Laotian Times

Immuno Cure starts HIV drug trial - Labiotech.eu

Immuno Cure starts HIV drug trial Labiotech.eu

Immuno Cure appoints new CFO - 美通社

Immuno Cure appoints new CFO 美通社

Immuno Cure secured maximum subsidy from HKSTP - Macau Business

Immuno Cure secured maximum subsidy from HKSTP Macau Business

Immuno Cure Successfully Admitted into the HKSTP Elite Programme - Laotian Times

Immuno Cure Successfully Admitted into the HKSTP Elite Programme Laotian Times

Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding - Media OutReach Newswire

Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding Media OutReach Newswire

ImmunoCure Inc Rebrands as Pozescaf - Launches New Era in Drug Discovery - CineJosh

ImmunoCure Inc Rebrands as Pozescaf - Launches New Era in Drug Discovery CineJosh

ImmunoCure is now Pozescaf. Launches New Era in Drug Discovery - TNILIVE

ImmunoCure is now Pozescaf. Launches New Era in Drug Discovery TNILIVE

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant